Latest encephalopathy Stories
Scientists have determined how a normal protein can be converted into a prion, an infectious agent that causes fatal brain diseases in humans and mammals.
SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc.
The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a deceased former college football player who died at age 42 was already suffering from the degenerative brain disease, Chronic Traumatic Encephalopathy (CTE).
A University of Toronto-led team of scientists says it has determined the evolutionary origin of the prion gene. The researchers said the diseased prion proteins are responsible for the fatal neurodegenerative Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy, also known as mad cow
ROCKVILLE, Md., Sept. 28 /PRNewswire-USNewswire/ -- According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy.
According to a study published on Wednesday, it appears that a variety of prion disease found in deer may be spread through the fecal matter of infected animals even when they exhibit no symptoms of the illness.
Up to 80 percent of cirrhotic patients develop difficulties with cognitive function.
A British expert on the human form of mad cow disease says it is essential that coroners test the brains and spleens of all young people who die. Professor John Collinge says without post-mortem tests for the infection it is impossible to get accurate information on how many people in Britain may be carrying it, The Times of London reported Wednesday.
Inhibiting an enzyme in the brains of newborns suffering from oxygen and blood flow deprivation stops a type of brain damage that is a leading cause of cerebral palsy, mental retardation and death, according to researchers at Cincinnati Children's Hospital Medical Center.
The Company also Initiates the Phase 2b ASTUTE Clinical Trial for Mild Hepatic Encephalopathy SAN DIEGO, April 28 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately held biopharmaceutical company, announced that data from its phase 2 study of AST-120 for the treatment of patients with low-grade hepatic encephalopathy was presented April 25th at the 44th Annual Meeting of the European Association for the Study of Liver Disease (EASL) in Copenhagen.
- totally perplexed and mixed up.